Loading organizations...
Loading organizations...
Endosense is a technology company.
Endosense develops advanced medical technology for contact-force measurement during catheter ablation procedures. Their core product, force-sensing ablation catheters like TactiCath, provides physicians with real-time feedback on the pressure applied to cardiac tissue. This innovation significantly enhances the reproducibility, efficacy, and safety of cardiac arrhythmia treatments by enabling more precise and controlled ablations.
The company was founded in Geneva in 2003 by Giovanni Leo. The foundational insight stemmed from the critical need within cardiology for objective, real-time data on catheter-tissue contact during ablation. Leo recognized that inconsistent contact force was a major variable affecting procedure outcomes, leading to the development of a solution that brought a new level of precision to a complex interventional therapy.
Endosense’s products are utilized by electrophysiologists and cardiologists globally who perform catheter ablation for various cardiac arrhythmias. The company's long-term vision is to standardize and optimize ablation procedures, ultimately improving patient outcomes and expanding access to highly effective treatments for heart rhythm disorders by providing tools for more consistent and predictable results.
Endosense has raised $150.6M across 5 funding rounds.
Endosense has raised $150.6M in total across 5 funding rounds.
Endosense SA was a medical technology company that developed the TactiCath, a force-sensing ablation catheter providing real-time contact force measurement to improve the efficacy, safety, and reproducibility of catheter ablation procedures for treating cardiac arrhythmias.[1][2][3] It served electrophysiologists and cardiac specialists addressing irregular heartbeats, solving challenges in ablation precision that reduced procedure success rates and increased risks like complications from inadequate tissue contact.[1][3] Founded in 2003, the company raised $100.6M before being acquired by St. Jude Medical, marking strong growth in the electrophysiology market.[1][3]
Note: A separate, newer entity at endosense.org focuses on at-home rapid tests for endometriosis using multiplexed lateral flow assays for protein and microRNA biomarkers, offering results in under 20 minutes for $30 to cut diagnostic delays and costs compared to invasive laparoscopy.[4] This profile centers on the acquired cardiac firm due to query alignment with historical tech records, but the diagnostics startup represents an emerging player in women's health.
Endosense SA was founded in 2003 in Geneva, Switzerland, as a medtech innovator targeting cardiac arrhythmias.[2][3] Backed by investors including Edmond de Rothschild Investment Partners, NeoMed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie, and NGN Capital, it pioneered contact-force measurement in ablation with proprietary Touch+ sensor technology.[2][3] Key milestones included the TactiCath launch, positive 12-month TOCCATA study data in 2010 confirming clinical benefits, and completion of the U.S. TOCCASTAR IDE trial by 2013, paving the way for FDA submission.[2][3] The company was acquired by St. Jude Medical, enhancing its atrial fibrillation portfolio and accelerating U.S. market entry.[3]
Endosense rode the early 2000s surge in catheter ablation for atrial fibrillation, a growing epidemic driven by aging populations and rising arrhythmia prevalence, where imprecise contact led to suboptimal outcomes.[1][3] Timing was ideal amid electrophysiology market expansion, with force-sensing addressing a critical gap in real-time feedback, influencing standards for safer minimally invasive cardiac interventions.[2][3] Its acquisition by St. Jude Medical integrated the tech into broader EP ecosystems, spurring innovations like AI-enhanced mapping and setting precedents for sensor-driven medtech that competitors like AutoGenomics or Seno Medical later emulated in diagnostics.[1][3]
Post-2013 acquisition, Endosense's TactiCath tech evolved within Abbott (via St. Jude legacy), likely fueling ongoing EP advancements amid rising AFib cases and ablation demand projected to grow with AI and robotics.[3] Trends like personalized cardiac care and minimally invasive devices will shape its legacy, amplifying influence in global arrhythmia management. Meanwhile, the newer EndoSense diagnostics startup could disrupt endometriosis care by scaling affordable at-home testing, tying back to medtech's shift toward accessible, patient-centric solutions that Endosense SA exemplified in cardiac innovation.[4]
Endosense has raised $150.6M in total across 5 funding rounds.
Endosense's investors include 3i, NeoMed Management, Andera Partners.
Endosense has raised $150.6M across 5 funding rounds. Most recently, it raised $29.4M Other Equity in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 21, 2024 | $29.4M Other Equity | 3i, NeoMed Management | |
| Nov 1, 2013 | $41.0M Series C | Andera Partners | |
| Mar 5, 2013 | $4.2M Series C Extension | ||
| Nov 1, 2012 | $40.0M Series C | Andera Partners | |
| Oct 1, 2009 | $36.0M Series B | Andera Partners |